At 3 mg daily, Liraglutide can reduce weight by a mean of 8%.31 The GLP‐1 analogues Liraglutide,32 Semaglutide,33 Exenatide LAR,34 Albiglutide,35 and Dulaglutide36 have recently been shown to reduce cardiovascular events (notably non‐fatal myocardial infarctions) in diabetic patients at high risk for cardiovascular disease, an effect that has been attributed to reduction in cardiovascular inflammation, although the exact mechanisms remain obscure.29 This evidence concerns the gene GLP1R and myocardial infarction.